NO20052979L - Propargyl trifluoromethoxy-amino-benzothiazole. - Google Patents
Propargyl trifluoromethoxy-amino-benzothiazole.Info
- Publication number
- NO20052979L NO20052979L NO20052979A NO20052979A NO20052979L NO 20052979 L NO20052979 L NO 20052979L NO 20052979 A NO20052979 A NO 20052979A NO 20052979 A NO20052979 A NO 20052979A NO 20052979 L NO20052979 L NO 20052979L
- Authority
- NO
- Norway
- Prior art keywords
- present
- alkyl
- integer
- propargyl
- benzothiazole
- Prior art date
Links
- YFYWJBQXRSDKNU-UHFFFAOYSA-N 5-prop-2-ynyl-4-(trifluoromethoxy)-1,3-benzothiazol-2-amine Chemical compound C#CCC1=CC=C2SC(N)=NC2=C1OC(F)(F)F YFYWJBQXRSDKNU-UHFFFAOYSA-N 0.000 title 1
- 229910052799 carbon Inorganic materials 0.000 abstract 4
- 125000006728 (C1-C6) alkynyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
hvori Ri er til stede eller fraværende, og når tilstede er H, C1-C6 alkyl, C1-C6 alkynyl, -(CH2)yS(CH2)xCH3, Ci-C6 aminoalkyl, Ci-C6 hydroksyalkyl eller -CCH2)nC(=O) (C6H4) (CH2)R2; R2 er H eller C1-C4 alkyl; R3 er H eller C1-C4 alkyl; R4 er til stede eller fraværende, og når tilstede er H, C1-C6 alkyl, C1-C6 alkynyl, -(CH2)yS(CH2)xCH3, Ci-C6 aminoalkyl, d-C6 hydroksyalkyl eller -(CH2)nC(=O)(C6H4)(CH2)R2; hvori n er et heltall på fra 1 -6; hvori x er 0 er et heltall på fra 1 -5 og y er et heltall på 1-5, slik at x+y<6; minst en av Ri eller R4 er til stede; den stiplede linjen representerer en binding mellom et av nitrogenatomene og det intervenerende karbonatomet; og en hvilken som helst forbindelse er ladet når både Ri og R4 er til stede, eller en hvilken som helst spesifikk enantiomer derav eller et hvilket som helst farmasøytisk akseptabelt salt derav, og en fremgangsmåte for behandling av en neurologisk forstyrrelse eller multiple sklerose ved administrasjon av en terapeutisk effektiv mengde av en hvilken som helst av forbindelsene.wherein R 1 is present or absent and when present is H, C 1 -C 6 alkyl, C 1 -C 6 alkynyl, - (CH 2) y S (CH 2) xCH 3, C 1 -C 6 aminoalkyl, C 1 -C 6 hydroxyalkyl or -CCH 2) nC (= O) (C6H4) (CH2) R2; R 2 is H or C 1 -C 4 alkyl; R 3 is H or C 1 -C 4 alkyl; R4 is present or absent and when present is H, C1-C6 alkyl, C1-C6 alkynyl, - (CH2) yS (CH2) xCH3, C1-C6 aminoalkyl, d-C6 hydroxyalkyl or - (CH2) nC (= O) (C6H4) (CH2) R2; wherein n is an integer of from 1 to 6; wherein x is 0 is an integer of 1 -5 and y is an integer of 1-5 such that x + y <6; at least one of R 1 or R 4 is present; the dotted line represents a bond between one of the nitrogen atoms and the intervening carbon atom; and any compound is charged when both R 1 and R 4 are present, or any specific enantiomer thereof or any pharmaceutically acceptable salt thereof, and a method of treating a neurological disorder or multiple sclerosis in the administration of a therapeutically effective amount of any of the compounds.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30154002A | 2002-11-21 | 2002-11-21 | |
| PCT/US2003/037592 WO2004047756A2 (en) | 2002-11-21 | 2003-11-20 | Propargyl-trifluoromethoxy-amino-benzothiazole derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20052979D0 NO20052979D0 (en) | 2005-06-17 |
| NO20052979L true NO20052979L (en) | 2005-08-19 |
Family
ID=32392394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20052979A NO20052979L (en) | 2002-11-21 | 2005-06-17 | Propargyl trifluoromethoxy-amino-benzothiazole. |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1569641A2 (en) |
| JP (1) | JP2006507350A (en) |
| KR (1) | KR20050083951A (en) |
| CN (1) | CN1741802A (en) |
| AU (1) | AU2003295898A1 (en) |
| BR (1) | BR0315704A (en) |
| CA (1) | CA2507414A1 (en) |
| IS (1) | IS7906A (en) |
| MX (1) | MXPA05005414A (en) |
| NO (1) | NO20052979L (en) |
| RU (1) | RU2005119307A (en) |
| WO (1) | WO2004047756A2 (en) |
| ZA (1) | ZA200504988B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012050971A2 (en) * | 2010-09-29 | 2012-04-19 | Teva Pharmaceutical Industries Ltd. | Propargyl-trifluoromethoxy-aminobenzothiazole derivatives, their preparation and use |
| CN103340859A (en) * | 2013-06-04 | 2013-10-09 | 中国科学院昆明动物研究所 | Method for establishing non-human primate animal model of Parkinson's disease by administration of MPP+ in lateral ventricle |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59112978A (en) * | 1982-12-21 | 1984-06-29 | Shionogi & Co Ltd | Propynylaminothiazole derivative |
-
2003
- 2003-11-20 RU RU2005119307/04A patent/RU2005119307A/en not_active Application Discontinuation
- 2003-11-20 MX MXPA05005414A patent/MXPA05005414A/en not_active Application Discontinuation
- 2003-11-20 KR KR1020057009216A patent/KR20050083951A/en not_active Withdrawn
- 2003-11-20 CA CA002507414A patent/CA2507414A1/en not_active Abandoned
- 2003-11-20 BR BR0315704-0A patent/BR0315704A/en not_active Application Discontinuation
- 2003-11-20 JP JP2004555702A patent/JP2006507350A/en active Pending
- 2003-11-20 EP EP03787112A patent/EP1569641A2/en not_active Withdrawn
- 2003-11-20 AU AU2003295898A patent/AU2003295898A1/en not_active Abandoned
- 2003-11-20 WO PCT/US2003/037592 patent/WO2004047756A2/en not_active Ceased
- 2003-11-20 ZA ZA200504988A patent/ZA200504988B/en unknown
- 2003-11-20 CN CNA2003801090823A patent/CN1741802A/en active Pending
-
2005
- 2005-06-17 NO NO20052979A patent/NO20052979L/en not_active Application Discontinuation
- 2005-06-22 IS IS7906A patent/IS7906A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004047756A2 (en) | 2004-06-10 |
| JP2006507350A (en) | 2006-03-02 |
| EP1569641A2 (en) | 2005-09-07 |
| NO20052979D0 (en) | 2005-06-17 |
| MXPA05005414A (en) | 2006-05-25 |
| ZA200504988B (en) | 2006-08-30 |
| RU2005119307A (en) | 2006-01-27 |
| WO2004047756A3 (en) | 2004-07-08 |
| KR20050083951A (en) | 2005-08-26 |
| BR0315704A (en) | 2005-09-06 |
| AU2003295898A1 (en) | 2004-06-18 |
| IS7906A (en) | 2005-06-22 |
| CA2507414A1 (en) | 2004-06-10 |
| CN1741802A (en) | 2006-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU1199A (en) | Benzosulfone derivatives | |
| HUP0002495A1 (en) | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use | |
| DE69931393D1 (en) | ANTITHROMBOTIC AMIDE | |
| HUP0400365A2 (en) | 3-fluoro-pyrrolidines as antidiabetic agents and pharmaceutical compositions containing the compounds | |
| MXPA03001072A (en) | The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands. | |
| HUP9900851A2 (en) | Use of benzotiophene derivatives for producing pharmaceuticals for inhibiting vascular smooth muscle cell migration | |
| TW200420542A (en) | A compound having TGF β inhibition activity and a medicinal composition containing the same | |
| ES2149350T3 (en) | PHARMACEUTICALLY ACTIVE COMPOUNDS AND LIPOSOMES AND METHODS FOR USE. | |
| MXPA04002167A (en) | 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases. | |
| HUP0303756A2 (en) | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands and process for their preparation and pharmaceutical compositions containing them | |
| MXPA03011244A (en) | New indole derivatives with 5-ht6 receptor affinity. | |
| MA26861A1 (en) | NON-PEPTIDIC INHIBITORS OF VLA-4 DEPENDENCY OF CELL BINDING USEFUL IN THE TREATMENT OF INFLAMMATORY, AUTOIMMUNE AND RESPIRATORY DISEASES | |
| HUP0302475A2 (en) | A method for treating allergies using substituted pyrazoles | |
| AU2330202A (en) | Treatment of statin side effects | |
| MY140525A (en) | Pharmaceutical uses for alpha2delta ligands | |
| TW427887B (en) | Pharmaceutical composition comprising a benzimidazole derivative for treating viral infections | |
| MXPA02001571A (en) | Method of cancer treatment. | |
| HUP9801946A2 (en) | A combination al medicament containing a 5-ht uptake inhibitor and a selective 5-ht1a antagonist and process for producing it | |
| AU2003274946A1 (en) | Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein | |
| HU9502456D0 (en) | Polyamine derivatives as radioprotective agents | |
| MXPA03000547A (en) | Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder. | |
| MA27257A1 (en) | COMPOUNDS USEFUL FOR THE TREATMENT OF COAL AND THE INHIBITION OF THE LETHAL GENE | |
| GEAP202516820A (en) | Prmt5-mta inhibitor | |
| HUP9901212A2 (en) | N-[2-(3-alkoxy-phenoxy)-ethyl]-dialkylamine derivatives, pharmaceutical compositions containing the same and their use as local anaesthetics | |
| HUP9901093A2 (en) | Use of benzotiophene derivatives for production of pharmaceuticals inhibiting melanoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |